All In MedTech

FDA Clearance Tracker · P990025-S067

NAVISTAR

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 8, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 8, 2022

Approved

Time to decision

251 days

Received Jun 30, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class II

The decision

FDA number
P990025-S067
Device name
NAVISTAR
Applicant location
Irvine, CA
Received
Jun 30, 2021
Decided
Mar 8, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990025

Device type

Device class
Class II
Regulation
21 CFR 870.1220
Specialty
Cardiology

Every decision under product code DRF

FDA's approval statement

As written in FDA's record.

Approval for the nGEN Generator (compatible with the THERMOCOOL, NAVISTAR and CELSIUS catheters), the addition of a manufacturing site in Israel to manufacture the nGEN Generator and nGEN Pump, and the addition of a manufacturing site in Mexico to manufacture the Interface Cable between the CELSIUS catheters to the nGEN Generator.

Source documents

Other decisions for Biosense Webster, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.